Related Experiment Video
Updated: Oct 25, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.0K
[Update Atrial Fibrillation - Current Management strategies]
Benjamin Schäffer1,2,3, Melanie A Gunawardene1,2,3, Stephan Willems1,2,3,4,5
1Klink für Kardiologie und Internistische Intensivmedizin Asklepios Klinik St. Georg, Hamburg, Deutschland.
Deutsche Medizinische Wochenschrift (1946)
|August 3, 2021
Summary
Atrial fibrillation (AF) management emphasizes early treatment. Oral anticoagulation and catheter ablation are key for preventing stroke and controlling symptoms in high-risk patients.
Area of Science:
- Cardiology
- Cardiac Electrophysiology
Background:
- Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia.
- Current research underscores the critical need for prompt AF management.
- The European Society of Cardiology has updated guidelines to optimize AF care.
Purpose of the Study:
- To summarize current recommendations for atrial fibrillation management.
- To highlight the importance of early intervention strategies in AF.
- To outline the role of anticoagulation and rhythm control in AF patients.
Main Methods:
- Review of the latest European Society of Cardiology guidelines for AF.
- Analysis of current studies on early treatment efficacy in AF.
- Synthesis of evidence regarding anticoagulation and rhythm control strategies.
Main Results:
- Oral anticoagulation is crucial for preventing thromboembolic events in at-risk AF patients.
- Non-vitamin K antagonist oral anticoagulants (NOAKs) are recommended as first-line therapy when feasible.
- Early rhythm control, including catheter ablation, is advised for symptomatic patients and those with heart failure.
Conclusions:
- Prompt initiation of treatment is essential for effective atrial fibrillation management.
- Catheter ablation offers an effective rhythm control option and should be considered early.
- Comprehensive AF management includes addressing risk factors and comorbidities alongside primary therapies.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
176
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
176
01:29Venous Thrombosis III: Interprofessional Care
66
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
66
01:26Mitral Stenosis III: Medical Management
57
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
57
01:26Atherosclerosis III: Management
77
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
77
01:30Heart Failure V: Medical Management
55
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
55
01:25Aortic Regurgitation III: Medical Management
87
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
87